Siste forsøk

EudraCT Number: 2022-002378-95

Sponsor Protocol Number: D7000C00001

Start Date: 2023-06-21

Sponsor Name: AstraZeneca AB

Full Title: A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions ...

Medical condition: COVID-19

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	10021881 - Infections and infestations	10051905	Coronavirus infection	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Ongoing) DK (Ongoing) DE (Ongoing) ES (Ongoing) SE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2022-000692-39

Sponsor Protocol Number: IVY

Start Date: 2023-06-19

Sponsor Name: Amsterdam University Medical Center

Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva

Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10068715	Fibrodysplasia ossificans progressiva	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002718-17

Sponsor Protocol Number: IMVT-1401-2401

Start Date: 2023-06-19

Sponsor Name: Immunovant Sciences, GmbH

Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004852	10077384	Chronic inflammatory demyelinating polyneuropathy	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) NO (Ongoing) FI (Ongoing) SE (Ongoing) DK (Ongoing) SK (Ongoing) BG (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003594-33

Sponsor Protocol Number: EORTC-1984-BCG

Start Date: 2023-06-16

Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE)

Medical condition: Triple negative breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075566	Triple negative breast cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002234-14

Sponsor Protocol Number: OR2805-101

Start Date: 2023-06-07

Sponsor Name: OncoResponse, Inc.

Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies

Medical condition: Solid tumor cancer

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) FR (Completed)

Trial results: (No results available)

EudraCT Number: 2022-003467-21

Sponsor Protocol Number: AROMUC5AC-1001

Start Date: 2023-06-07

Sponsor Name: Arrowhead Pharmaceuticals, Inc.

Full Title: A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Asthma

Medical condition: Asthma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10038738 - Respiratory, thoracic and mediastinal disorders	10003553	Asthma	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Ongoing) PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-001403-33

Sponsor Protocol Number: TCTLR-101

Start Date: 2023-06-06

Sponsor Name: Ascendis Pharma Oncology Division A/S

Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...

Medical condition: Locally advanced or metastatic solid tumor malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10049280	Solid tumour	LLT
	21.1	100000004864	10065143	Malignant solid tumour	LLT
	21.1	100000004864	10065147	Malignant solid tumor	LLT
	21.1	100000004864	10065252	Solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Ongoing) PL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2022-002313-41

Sponsor Protocol Number: CRC2021-02

Start Date: 2023-06-06

Sponsor Name: CENTRO RICERCHE CLINICHE DI VERONA

Full Title: A PHASE 2, MULTICENTER, OPEN LABEL, CLINICAL TRIAL EVALUATING SAFETY AND ACTIVITY OF NIVOLUMAB/IPILIMUMAB AND CHEMOTHERAPY COMBINATION IN ADVANCED NSCLC PATIENTS WITH HIV, HBV, HCV AND POST-ACUTE S...

Medical condition: advanced non-small-cell lung cancer (NSCLC) (both squamous and non-squamous) in patients with chronic viral infections or sequalae from Sars-Cov2 infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071533	Lung squamous cell carcinoma metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10079440	Non-squamous non-small cell lung cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2022-000690-73

Sponsor Protocol Number: BAY86-5321/21912

Start Date: 2023-06-06

Sponsor Name: Bayer AG

Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...

Medical condition: Neovascular (wet) age-related macular degeneration

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10015919 - Eye disorders	10071129	Neovascular age-related macular degeneration	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000054-28

Sponsor Protocol Number: OLIGOTREAT

Start Date: 2023-06-02

Sponsor Name: Klinikum der Universität München

Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

Medical condition: Schizophrenia

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10037175 - Psychiatric disorders	10039626	Schizophrenia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

Siste forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner